New study tracks hidden side effects of melanoma immunotherapy

NCT ID NCT07148245

Recruiting now Knowledge-focused Sponsor: University of California, San Francisco Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study follows 300 adults with advanced melanoma who are receiving immune checkpoint inhibitors. Researchers will collect blood samples, quality-of-life surveys, and medical records to track symptoms over time. The goal is to identify patterns and risk factors for worse symptoms, helping doctors catch side effects early and improve treatment decisions.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could help doctors better predict and manage side effects from immunotherapy, improving quality of life for melanoma patients.
What could go wrong: This is an observational study, not a treatment trial. It will not test a new drug or therapy, and results may not lead to immediate changes in care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CUTANEOUS MELANOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cutaneous melanoma melanoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CUTANEOUS MELANOMA CUTANEOUS MELANOMA BY AJCC V7 STAGE CUTANEOUS MELANOMA, STAGE III CUTANEOUS MELANOMA, STAGE IV

Contacts and locations

Show contact details

Locations

University of California, San Francisco
RECRUITING

San Francisco, California, 94143, United States

Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.